Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples